JP2023527422A5 - - Google Patents

Info

Publication number
JP2023527422A5
JP2023527422A5 JP2022573297A JP2022573297A JP2023527422A5 JP 2023527422 A5 JP2023527422 A5 JP 2023527422A5 JP 2022573297 A JP2022573297 A JP 2022573297A JP 2022573297 A JP2022573297 A JP 2022573297A JP 2023527422 A5 JP2023527422 A5 JP 2023527422A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cells
subject
viral infection
lactoferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527422A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034234 external-priority patent/WO2021242850A1/en
Publication of JP2023527422A publication Critical patent/JP2023527422A/ja
Publication of JP2023527422A5 publication Critical patent/JP2023527422A5/ja
Pending legal-status Critical Current

Links

JP2022573297A 2020-05-28 2021-05-26 ＳＡＲＳ－ＣｏＶ－２感染を予防および治療するための組成物および方法 Pending JP2023527422A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031310P 2020-05-28 2020-05-28
US63/031,310 2020-05-28
PCT/US2021/034234 WO2021242850A1 (en) 2020-05-28 2021-05-26 Compositions and methods for preventing and treating sars-cov-2 infection

Publications (2)

Publication Number Publication Date
JP2023527422A JP2023527422A (ja) 2023-06-28
JP2023527422A5 true JP2023527422A5 (enExample) 2024-06-21

Family

ID=78722710

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573297A Pending JP2023527422A (ja) 2020-05-28 2021-05-26 ＳＡＲＳ－ＣｏＶ－２感染を予防および治療するための組成物および方法

Country Status (4)

Country Link
US (1) US20240016901A1 (enExample)
EP (1) EP4157327A4 (enExample)
JP (1) JP2023527422A (enExample)
WO (1) WO2021242850A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12450735B2 (en) * 2021-09-02 2025-10-21 Memorial Sloan-Kettering Cancer Center Learning representations of nuclei in histopathology images with contrastive loss
EP4148042A1 (en) * 2021-09-10 2023-03-15 Centre National de la Recherche Scientifique Phenoxy-acetyl-thioureido-benzenesulfonamide derivatives, and their uses
WO2023147186A2 (en) * 2022-01-31 2023-08-03 Kotlyar David Transgenic seeds for inhibiting viral replication via anticommunicable fortification system (acf system) with concomitant method of treatment or prevention of viral disease, and pandemic prevention and elimination
CN116115611A (zh) * 2022-11-07 2023-05-16 靖江市人民医院 甲磺酸洛美他派在制备抑制新型冠状病毒的产品中的应用
WO2025245059A1 (en) * 2024-05-23 2025-11-27 Yale University Compositions comprising gsk-3 and/or beta-catenin inhibitors and/or degraders and methods of use thereof
CN121227875B (zh) * 2025-11-26 2026-04-10 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 一种抗病毒药物筛选标志物、微粒体甘油三酯转移蛋白抑制剂在制备抗病毒药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CN101715349B (zh) * 2007-05-08 2012-07-18 美国Rq生物科技有限公司 治疗革兰氏阴性细菌感染的治疗组合物及方法
US20170296530A1 (en) * 2012-07-03 2017-10-19 Justice E. OBI Compositions and Methods for Treating and Inhibiting Viral Infections
WO2014122537A2 (en) * 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
AU2014310935B2 (en) * 2013-08-21 2019-11-21 CureVac SE Combination vaccine
KR20230156963A (ko) * 2014-10-07 2023-11-15 엠와이알 게엠베하 Hbv 및 hdv 감염의 조합 치료법
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
CN111097040A (zh) * 2020-02-19 2020-05-05 苟春虎 抗病毒清肺肽
IT202000005026A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso inalatorio ad azione antivirale
IT202000005011A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso orale ad azione antivirale
GB2593452A (en) * 2020-03-16 2021-09-29 Mead Johnson Nutrition Co Use of lactoferrin
US20230149515A1 (en) * 2020-04-29 2023-05-18 The Regents Of The University Of Michigan Inhibition of sars-cov-2 viral entry through oral administration of lactoferrin and uses thereof

Similar Documents

Publication Publication Date Title
JP2023527422A5 (enExample)
JP7359519B2 (ja) ライノウイルス感染症の予防又は治療のための薬物
JP2023520591A5 (enExample)
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
TW201919675A (zh) 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
Liu et al. Electroacupuncture attenuates brain injury through α7 nicotinic acetylcholine receptor-mediated suppression of neuroinflammation in a rat model of asphyxial cardiac arrest
Lupfer et al. Inhalation of sodium pyruvate to reduce the symptoms and severity of respiratory diseases including COVID-19, long COVID, and pulmonary fibrosis
CN114246937B (zh) 白细胞介素37与干扰素联用在治疗病毒感染中的应用
CN112220913A (zh) TFF2蛋白和IFN-κ蛋白联用在治疗新型冠状病毒感染中的应用
CN119015294A (zh) 灵芝酸d在制备抗老年性骨质疏松症药物中的应用
US20240123060A1 (en) Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
JP7850132B2 (ja) ＳＡＲＳ－ＣｏＶ－２感染患者におけるアウトカムを改善するための吸入インターフェロン－ベータ
CN110548132A (zh) TGF-β1蛋白在制备治疗抑郁症的药物中的应用
CN116473979A (zh) 甲基巴多索隆在制备抑制呼吸道合胞病毒感染药物中的应用
WO2022024108A1 (en) Ezrin peptide (hep-1) for use in the treatment of coronavirus disease
JP6528314B2 (ja) Ａ（Ｈ１Ｎ１）ｐｄｍ０９インフルエンザウイルス感染による気管支喘息の予防又は改善剤
CN102670684B (zh) 白薇总皂苷的应用
JP2002515035A (ja) アミノステロール化合物の治療学的使用
KR20230138643A (ko) 감염병 동반된 전신경화증 환자치료약물 스크리닝 플랫폼 모델
KR102914953B1 (ko) 질레우톤(zileuton)을 유효성분으로 포함하는 피부 방사선 증후군 예방 또는 치료용 약학 조성물
TWI923237B (zh) Covid-19疫苗在製備用於治療或預防ｂ型肝炎的藥物中的用途
CN111281893B (zh) 注射用母牛分枝杆菌在制备用于防治covid-19的药物中的应用
WO2024120452A1 (en) Compositions and methods for prophylaxis and treatment of covid-19
JP2023525522A (ja) Ｃｏｖｉｄ－１９の治療または予防用ペプチド
RU2305555C1 (ru) Способ иммунокоррекции при пневмонии